What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cholesterol
His scientific interests lie mostly in Internal medicine, Endocrinology, Cholesterol, Myocardial infarction and Pravastatin.
The various areas that Chris J. Packard examines in his Internal medicine study include Surgery and Cardiology.
His studies deal with areas such as Framingham Risk Score and Case-control study as well as Cardiology.
His study focuses on the intersection of Cholesterol and fields such as Blood plasma with connections in the field of Differential centrifugation, Ultracentrifuge, Arteriosclerosis, Preeclampsia and Gestational age.
His study in Myocardial infarction is interdisciplinary in nature, drawing from both Stroke, Vascular disease, Bioinformatics and Hazard ratio.
His Pravastatin study combines topics from a wide range of disciplines, such as Randomized controlled trial, Heart Protection Study and Gerontology.
His most cited work include:
- Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (6962 citations)
- Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial (2750 citations)
- Major lipids, apolipoproteins, and risk of vascular disease (1765 citations)
What are the main themes of his work throughout his whole career to date?
Chris J. Packard focuses on Internal medicine, Endocrinology, Cholesterol, Lipoprotein and Apolipoprotein B.
Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Cardiology.
His research in Cardiology focuses on subjects like Risk factor, which are connected to Vascular disease and Diabetes mellitus.
The study incorporates disciplines such as Lipoprotein lipase and Lipolysis in addition to Apolipoprotein B.
His studies in Pravastatin integrate themes in fields like Prospective cohort study, Surgery, Stroke, Myocardial infarction and Hazard ratio.
His research investigates the connection between Myocardial infarction and topics such as Statin that intersect with problems in Clinical trial.
He most often published in these fields:
- Internal medicine (70.00%)
- Endocrinology (49.05%)
- Cholesterol (26.90%)
What were the highlights of his more recent work (between 2013-2021)?
- Internal medicine (70.00%)
- Endocrinology (49.05%)
- Cholesterol (26.90%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Endocrinology, Cholesterol, Apolipoprotein B and Triglyceride.
His research related to Myocardial infarction, Statin, Lipoprotein, Disease and Randomized controlled trial might be considered part of Internal medicine.
His Myocardial infarction study also includes fields such as
- Stroke and related Physical therapy and Ezetimibe,
- Pravastatin which connect with Hazard ratio.
His Cholesterol study combines topics in areas such as Coronary heart disease and Odds ratio.
His work deals with themes such as Chylomicron, Hypertriglyceridemia and Apolipoprotein C-III, which intersect with Apolipoprotein B.
His Triglyceride study integrates concerns from other disciplines, such as Triglyceride transport and Metabolism.
Between 2013 and 2021, his most popular works were:
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (944 citations)
- Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease (279 citations)
- Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (219 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Enzyme
Internal medicine, Myocardial infarction, Randomized controlled trial, Bioinformatics and Cholesterol are his primary areas of study.
The Internal medicine study combines topics in areas such as Endocrinology and Surgery.
His research integrates issues of Fructose and Heterozygote advantage in his study of Endocrinology.
His Myocardial infarction research integrates issues from Stroke, Lower risk and Pravastatin.
His research in Randomized controlled trial intersects with topics in Relative risk, Prospective cohort study, Mendelian Randomization Analysis and Disease.
His Cholesterol research is multidisciplinary, incorporating perspectives in Receptor, Knockout mouse and Acute-phase protein.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
